A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea

Jae Seung Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Jin Sil Seong, Kwang Hyub Han, Do Young Kim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background/Aims: Transarterial chemoembolization (TACE) is a standard treatment for intermediate-stage hepatocellular carcinoma (HCC), but there is much controversy about TACE refractoriness. The aim of this study was to identify trends in the actual clinical application of TACE and recognition of TACE refractoriness by Korean experts. Methods: In total, 17 questionnaires on TACE refractoriness were administered to 161 clinicians via an online survey. Multiple answers were allowed for some questions. Results: Most clinicians agreed that there is a need for standardization of TACE application through specific scoring systems (n=124, 77.0%). TACE refractoriness was predominantly expected by participants when recurrences were detected within 1 month (n=70, 43.5%), there were 4 to 6 tumors (n=77, 47.8%), the maximal tumor size was 3–5 cm (n=49, 30.4%), and when there was insufficient tumor necrosis despite TACE being repeated more than three times (n=78, 48.4%). Overall, sorafenib therapy (n=137) and radiotherapy (n=114) were preferred when repeated TACE was considered ineffective. Conclusions: Treatment of HCC is often based on the clinical judgment of clinicians because of the heterogeneity among individuals. Experts need to continue discussions on the standardization and sub-classification of HCC treatment guidelines in Korea. (Clin Mol Hepatol 2020;26:24-32).

Original languageEnglish (US)
Pages (from-to)24-32
Number of pages9
JournalClinical and Molecular Hepatology
Volume26
Issue number1
DOIs
StatePublished - Jan 2020

Fingerprint

Korea
Hepatocellular Carcinoma
Neoplasms
Therapeutics
Necrosis
Radiotherapy
Guidelines
Recurrence
Surveys and Questionnaires

Keywords

  • Carcinoma
  • Embolization
  • Hepatocellular
  • Liver neoplasms
  • Surveys and questionnaires
  • Therapeutic

ASJC Scopus subject areas

  • Hepatology
  • Molecular Biology

Cite this

A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea. / Lee, Jae Seung; Kim, Beom Kyung; Kim, Seung Up; Park, Jun Yong; Ahn, Sang Hoon; Seong, Jin Sil; Han, Kwang Hyub; Kim, Do Young.

In: Clinical and Molecular Hepatology, Vol. 26, No. 1, 01.2020, p. 24-32.

Research output: Contribution to journalArticle

Lee, Jae Seung ; Kim, Beom Kyung ; Kim, Seung Up ; Park, Jun Yong ; Ahn, Sang Hoon ; Seong, Jin Sil ; Han, Kwang Hyub ; Kim, Do Young. / A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea. In: Clinical and Molecular Hepatology. 2020 ; Vol. 26, No. 1. pp. 24-32.
@article{e8edd5dc4195429fa4d98e644eabdd45,
title = "A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea",
abstract = "Background/Aims: Transarterial chemoembolization (TACE) is a standard treatment for intermediate-stage hepatocellular carcinoma (HCC), but there is much controversy about TACE refractoriness. The aim of this study was to identify trends in the actual clinical application of TACE and recognition of TACE refractoriness by Korean experts. Methods: In total, 17 questionnaires on TACE refractoriness were administered to 161 clinicians via an online survey. Multiple answers were allowed for some questions. Results: Most clinicians agreed that there is a need for standardization of TACE application through specific scoring systems (n=124, 77.0{\%}). TACE refractoriness was predominantly expected by participants when recurrences were detected within 1 month (n=70, 43.5{\%}), there were 4 to 6 tumors (n=77, 47.8{\%}), the maximal tumor size was 3–5 cm (n=49, 30.4{\%}), and when there was insufficient tumor necrosis despite TACE being repeated more than three times (n=78, 48.4{\%}). Overall, sorafenib therapy (n=137) and radiotherapy (n=114) were preferred when repeated TACE was considered ineffective. Conclusions: Treatment of HCC is often based on the clinical judgment of clinicians because of the heterogeneity among individuals. Experts need to continue discussions on the standardization and sub-classification of HCC treatment guidelines in Korea. (Clin Mol Hepatol 2020;26:24-32).",
keywords = "Carcinoma, Embolization, Hepatocellular, Liver neoplasms, Surveys and questionnaires, Therapeutic",
author = "Lee, {Jae Seung} and Kim, {Beom Kyung} and Kim, {Seung Up} and Park, {Jun Yong} and Ahn, {Sang Hoon} and Seong, {Jin Sil} and Han, {Kwang Hyub} and Kim, {Do Young}",
year = "2020",
month = "1",
doi = "10.3350/cmh.2018.0065",
language = "English (US)",
volume = "26",
pages = "24--32",
journal = "Clinical and molecular hepatology",
issn = "2287-2728",
publisher = "Korean Association for the Study of the Liver",
number = "1",

}

TY - JOUR

T1 - A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea

AU - Lee, Jae Seung

AU - Kim, Beom Kyung

AU - Kim, Seung Up

AU - Park, Jun Yong

AU - Ahn, Sang Hoon

AU - Seong, Jin Sil

AU - Han, Kwang Hyub

AU - Kim, Do Young

PY - 2020/1

Y1 - 2020/1

N2 - Background/Aims: Transarterial chemoembolization (TACE) is a standard treatment for intermediate-stage hepatocellular carcinoma (HCC), but there is much controversy about TACE refractoriness. The aim of this study was to identify trends in the actual clinical application of TACE and recognition of TACE refractoriness by Korean experts. Methods: In total, 17 questionnaires on TACE refractoriness were administered to 161 clinicians via an online survey. Multiple answers were allowed for some questions. Results: Most clinicians agreed that there is a need for standardization of TACE application through specific scoring systems (n=124, 77.0%). TACE refractoriness was predominantly expected by participants when recurrences were detected within 1 month (n=70, 43.5%), there were 4 to 6 tumors (n=77, 47.8%), the maximal tumor size was 3–5 cm (n=49, 30.4%), and when there was insufficient tumor necrosis despite TACE being repeated more than three times (n=78, 48.4%). Overall, sorafenib therapy (n=137) and radiotherapy (n=114) were preferred when repeated TACE was considered ineffective. Conclusions: Treatment of HCC is often based on the clinical judgment of clinicians because of the heterogeneity among individuals. Experts need to continue discussions on the standardization and sub-classification of HCC treatment guidelines in Korea. (Clin Mol Hepatol 2020;26:24-32).

AB - Background/Aims: Transarterial chemoembolization (TACE) is a standard treatment for intermediate-stage hepatocellular carcinoma (HCC), but there is much controversy about TACE refractoriness. The aim of this study was to identify trends in the actual clinical application of TACE and recognition of TACE refractoriness by Korean experts. Methods: In total, 17 questionnaires on TACE refractoriness were administered to 161 clinicians via an online survey. Multiple answers were allowed for some questions. Results: Most clinicians agreed that there is a need for standardization of TACE application through specific scoring systems (n=124, 77.0%). TACE refractoriness was predominantly expected by participants when recurrences were detected within 1 month (n=70, 43.5%), there were 4 to 6 tumors (n=77, 47.8%), the maximal tumor size was 3–5 cm (n=49, 30.4%), and when there was insufficient tumor necrosis despite TACE being repeated more than three times (n=78, 48.4%). Overall, sorafenib therapy (n=137) and radiotherapy (n=114) were preferred when repeated TACE was considered ineffective. Conclusions: Treatment of HCC is often based on the clinical judgment of clinicians because of the heterogeneity among individuals. Experts need to continue discussions on the standardization and sub-classification of HCC treatment guidelines in Korea. (Clin Mol Hepatol 2020;26:24-32).

KW - Carcinoma

KW - Embolization

KW - Hepatocellular

KW - Liver neoplasms

KW - Surveys and questionnaires

KW - Therapeutic

UR - http://www.scopus.com/inward/record.url?scp=85071174774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071174774&partnerID=8YFLogxK

U2 - 10.3350/cmh.2018.0065

DO - 10.3350/cmh.2018.0065

M3 - Article

C2 - 31104456

AN - SCOPUS:85071174774

VL - 26

SP - 24

EP - 32

JO - Clinical and molecular hepatology

JF - Clinical and molecular hepatology

SN - 2287-2728

IS - 1

ER -